Literature DB >> 21431458

[Clinical and imaging diagnostics of Parkinson's disease and multiple system atrophy].

K I Schmidt1, J Spiegel, W Reith.   

Abstract

The diagnosis of Parkinson's disease (PD) and multiple system atrophy (MSA) is primarily made by clinical symptoms, but might still remain challenging even for experienced neurologists. Neuroradiologic imaging may be a useful tool in the diagnostic work-up, particularly for excluding other diseases, such as normal pressure hydrocephalus, multi-infarct dementia and cerebellar lesions. Nuclear medicine methods can additionally support the diagnosis and differential diagnosis of PD and MSA.

Entities:  

Mesh:

Year:  2011        PMID: 21431458     DOI: 10.1007/s00117-010-2095-5

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  40 in total

Review 1.  The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes.

Authors:  S Braune
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

2.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 3.  Nuclear medicine imaging of pheochromocytoma and neuroblastoma.

Authors:  J C Sisson; B L Shulkin
Journal:  Q J Nucl Med       Date:  1999-09

4.  (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

Authors:  S Orimo; E Ozawa; S Nakade; T Sugimoto; H Mizusawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-08       Impact factor: 10.154

5.  What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study.

Authors:  I Litvan; C G Goetz; J Jankovic; G K Wenning; V Booth; J J Bartko; A McKee; K Jellinger; E C Lai; J P Brandel; M Verny; K R Chaudhuri; R K Pearce; Y Agid
Journal:  Arch Neurol       Date:  1997-08

6.  Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.

Authors:  B Shapiro; J E Copp; J C Sisson; P L Eyre; J Wallis; W H Beierwaltes
Journal:  J Nucl Med       Date:  1985-06       Impact factor: 10.057

7.  123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Authors:  A Antonini; R Benti; R De Notaris; S Tesei; A Zecchinelli; G Sacilotto; N Meucci; M Canesi; C Mariani; G Pezzoli; P Gerundini
Journal:  Neurol Sci       Date:  2003-10       Impact factor: 3.307

8.  How useful is [123I]beta-CIT SPECT in clinical practice?

Authors:  J Eerola; P J Tienari; S Kaakkola; P Nikkinen; J Launes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

9.  Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies.

Authors:  Yume Okada; Yuji Ito; Junko Aida; Masahiro Yasuhara; Shin-ichiro Ohkawa; Katsuiku Hirokawa
Journal:  Pathol Int       Date:  2004-09       Impact factor: 2.534

10.  Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease.

Authors:  Jörg Spiegel; Dirk Hellwig; Georgios Farmakis; Wolfgang H Jost; Samuel Samnick; Klaus Fassbender; Carl-Martin Kirsch; Ulrich Dillmann
Journal:  Mov Disord       Date:  2007-05-15       Impact factor: 10.338

View more
  2 in total

1.  [MRI in dementia-type diseases].

Authors:  S V Bodea; R Mühl-Benninghaus
Journal:  Radiologe       Date:  2015-05       Impact factor: 0.635

Review 2.  [Degenerative cerebellar diseases and differential diagnoses].

Authors:  W Reith; S Roumia; P Dietrich
Journal:  Radiologe       Date:  2016-11       Impact factor: 0.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.